^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    GemPred signature

    6ms
    Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial. (PubMed, J Clin Oncol)
    This ancillary study of a phase III randomized trial demonstrates that among the quarter of patients with a GemPred-positive transcriptomic signature, survival was comparable with that of mFOLFIRINOX, whereas those receiving adjuvant gemcitabine had fewer adverse events.
    Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    GemPred signature
    |
    gemcitabine • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium